Загрузка страницы

Invitation to HIV Prevention Review Meeting 2021 by Linda-Gail Bekker

Linda-Gail Bekker from Desmond Tutu HIV Foundation / University of Cape Town (UCT), South Africa will be presenting during Session 2: Long-Acting Injectable PrEP – at the HIV Prevention Review Meeting 2021 on 2 June 2021

Learn more about the program: https://bit.ly/2Rmsk4x
For direct registration: https://bit.ly/3hy97aG

Join this meeting to receive the latest clinical recommendations from world-leading experts. Explore abstract-driven presentations, and dive into truly global round table discussions.

Speaker: Linda-Gail Bekker, MBCHB, DTMH, DCH, FCP(SA), PhD
Desmond Tutu HIV Foundation / University of Cape Town (UCT), South Africa

PROGRAM | Wednesday, 2 June 2021
Plenary Talk
Session1 | Oral PrEP Today – Where Do We Stand?
Session 2 | Long-Acting Injectable PrEP
Roundtable Discussion: Where Is HIV Prevention Going?
Learn more about the HIV Prevention Review Meeting 2021 that will take place virtually 2 June 2021 via https://bit.ly/2Rmsk4x

HIV prevention is in the midst of an exciting chapter, with several different drugs and formulations being investigated or already available to prevent HIV acquisition. This wealth of new data and knowledge, being present at the major conferences, comes hand-in-hand with a need to review the importance of these findings and their implications for the implementation of prevention programs. The Prevention 2021 review meeting aims at bridging this gap to consolidate the implications of the new data presented at the last conferences, and thus extrapolates the impact of the latest emerging data.

To become acquainted with the HIV Prevention Review Meeting 2021, visit https://bit.ly/2Rmsk4x​

For more medical education programs, as well as the latest scientific information, visit https://academicmedicaleducation.com/

Видео Invitation to HIV Prevention Review Meeting 2021 by Linda-Gail Bekker канала Academic Medical Education
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
26 мая 2021 г. 19:50:23
00:00:33
Другие видео канала
Preview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCPreview: Highlights International Workshop on HIV & Women 2021 | Sharon Walmsley, FRCPC, MD, MSCA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDA new model for early clinical development of TB drugs and its application... | Norbert Heinrich, MDClinical Considerations of Aging People Living with HIV - Marta BoffitoClinical Considerations of Aging People Living with HIV - Marta BoffitoThe ABC of viral hepatitis | Mark Thursz, MRCPThe ABC of viral hepatitis | Mark Thursz, MRCPUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDUpdates on WHO HIV Treatment Guidelines - Fujie Zhang, MD, PhDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs HCV drug resistance an issue? | Jürgen Rockstroh, MDIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFIs NAFLD/NASH a Public Health Challenge in 2022? - Zobair M. Younossi, MD, MPH, FACG, FACP, AGAFAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunAntiretroviral Therapy in Pregnant Women with HIV and Neonates - Lijun SunLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDLong Acting Antivirals for Treatment and Prevention | Martin Markowitz, MDExercise and aging | Wendy Kohrt, PhDExercise and aging | Wendy Kohrt, PhDSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionSymposium 1: ViiV - What’s New in HIV Treatment & Prevention for Youth? - Panel DiscussionInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchInvitation to join the HIV Prevention Review Meeting 2022 - 30-31 MarchCase-Based Discussion of Oral Antivirals for COVID-19: Part 1  - Catia Marzolini, PharmD, PhDCase-Based Discussion of Oral Antivirals for COVID-19: Part 1 - Catia Marzolini, PharmD, PhDAnti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonAnti-HBV potential of PD-1/PD-L1 blockade in chronic HBV infection | Daniel VerdonResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissResearch into Aging with HIV: Lessons Learned and Outstanding Challenges - Peter ReissState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaState of the Art Interventions in Improving Pediatric HIV Outcomes in OVC Programs - Grace MayanjaUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDUsing Infant Animal Models to Advance Pediatric HIV Prevention, Vaccines .. | Ann Chahroudi, MD, PhDInvitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Invitation by Roger Paredes, MD, PhD | European Meeting on HIV & Hepatitis 2021Differentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDDifferentiated & Simplified PrEP for HIV Prevention | Heather-Marie Schmidt, BMedSc (Hon), MPH, PhDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDAcute hepatitis A to E, diagnosis and management | Thomas Berg, MDDoes resistance still matter? | Daniel Kuritzkes, MDDoes resistance still matter? | Daniel Kuritzkes, MD
Яндекс.Метрика